| Literature DB >> 21903431 |
Adele D'Amico1, Michela Catteruccia, Fabrizio De Benedetti, Marina Vivarelli, Manuela Colucci, Simona Cascioli, Enrico Bertini.
Abstract
Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21903431 DOI： 10.1016/j.ejpn.2011.08.002
Source DB: PubMed Journal: Eur J Paediatr Neurol ISSN： 1090-3798 Impact factor: 3.140